What are HDAC inhibitor drugs?

HDAC inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting H3 histone deacetylase (HDAC)). 0 are currently marketed, with 5 more in clinical development.

HDAC inhibitor

0 marketed 4 in Phase 3 1 in Phase 2

This page covers all HDAC inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting H3 histone deacetylase (HDAC), HDAC, Histone deacetylase (HDAC).

Targets

H3 histone deacetylase (HDAC) · HDAC · Histone deacetylase (HDAC) · HDAC6

Phase 3 pipeline (4)

VDPHL01 · Veradermics, Inc. · Oncology
VDPHL01 is a small molecule that targets the H3 histone deacetylase (HDAC) enzyme.
SHR2554; Chidamide analog tablets · Jiangsu HengRui Medicine Co., Ltd. · Oncology
Chidamide analog SHR2554 is an inhibitor of histone deacetylases (HDACs), which play a role in regulating gene expression.
HLD200 · Ironshore Pharmaceuticals and Development, Inc · Oncology
HLD200 is a histone deacetylase (HDAC) inhibitor that modulates gene expression by blocking HDAC enzymes.
VDPHL01 QD · Veradermics, Inc. · Inflammatory diseases
VDPHL01 QD is a small molecule that targets the H3 histone deacetylase (HDAC) to modulate gene expression.

Phase 2 pipeline (1)

CEM-101 · Melinta Therapeutics, Inc. · Oncology
CEM-101 is a potent and selective inhibitor of the histone deacetylase 6 (HDAC6) enzyme.